Medtronic
Logotype for Medtronic plc

Medtronic (MDT) investor relations material

Medtronic Morgan Stanley 24th Annual Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Medtronic plc
Morgan Stanley 24th Annual Global Healthcare Conference summary15 Sep, 2026

Market and portfolio performance

  • Acute procedure volumes remain strong, with key franchises like Cardiac Rhythm Management and spine showing robust growth, supported by a favorable payer mix and strong free cash flow performance in challenging geographies.

  • AI integration is enhancing both product capabilities and internal efficiencies, improving outcomes, workflow, and enabling monetization through stickier, higher-value offerings like StealthAXiS and GI Genius.

  • Growth is driven by innovation across both new and established franchises, with a vitality index rising to the low-to-mid 20s, reflecting a higher proportion of revenue from recently launched products.

  • Four generational growth drivers—cardiac ablation, renal denervation, Hugo robotics, and Altaviva pelvic health—are at different stages, each contributing to sustained top-line expansion.

  • Neuroscience is expected to accelerate in the second half of the year, supported by recent acquisitions and a strong product pipeline.

Strategic investments and portfolio management

  • Major investment in a soft tissue robot in China (Cornerstone) complements the Hugo platform, expanding customer choice and accelerating leadership in robotic surgery.

  • Structural heart remains a profitable, growing segment with renewed investment in both inorganic (Anteris, Pi-Cardia) and organic programs, aiming for higher growth rates in coming years.

  • Portfolio rationalization continues, with the recent MiniMed spin-out allowing focus on higher-return cardiovascular, MedSurg, and neuroscience segments, and ongoing SKU-level optimization.

  • M&A activity has increased, with $2.7 billion spent over the past year on tuck-in acquisitions and ventures, targeting innovation acceleration without large-scale deals.

  • Earnings dilution from acquisitions is managed through embedded guidance, leveraging gross margin improvements and reinvestment in innovation.

Operational improvements and outlook

  • Operational enhancements, including Kaizen and design-to-cost strategies, are expected to drive margin expansion, aiming to return to pre-COVID gross margin levels.

  • FY 2027 revenue guidance is underpinned by continued cardiovascular strength, accelerating neuroscience, and MedSurg momentum, with growth drivers providing additional runway.

  • Capital allocation prioritizes dividends, increased M&A for growth, and a dual-track approach to innovation through both organic and inorganic initiatives.

  • Sustained sales growth in the 6% range is supported by a stronger base and sequential generational growth drivers, with further details to be shared at the upcoming Investor Day.

  • The company is focused on delivering both growth and leverage, aiming for sustainable EPS improvement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Medtronic earnings date

Logotype for Medtronic plc
Q2 202724 Nov, 2026
Medtronic
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Medtronic earnings date

Logotype for Medtronic plc
Q2 202724 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

A leader in global medtech industry

If you were to examine different hospitals' surgical imaging machines or pacemakers worldwide, the importance of Medtronic would soon become very clear. Medtronic is probably one of the most innovative companies in the world. Over their 70-year lifetime, Medtronic has grown from being a small electrical repair shop in a Minneapolis garage to a global leader in medical technology with a market cap north of $100 billion.

Owner of more than 49,000 patents

Medtronic treats more than 70 health conditions, from Parkinson’s and chronic heart conditions to diabetes, helping over 100 million people worldwide every year. They are one of the leaders in the global Medtech industry and are growing both organically and through M&A. In fact, Medtronic has done, on average, one acquisition every five months over the last decade.

Their four main business segments are:

  • Cardiac and Vascular

  • Minimally Invasive Therapies

  • Restorative Therapies

  • Diabetes

Medtronic is mainly known for their revolutionary cardiac devices – battery-powered miniature pacemakers – but have a wide product portfolio, including defibrillators, vessel sealing instruments, mesh and spinal implants, bone graft substitutes, highly advanced insulin pumps, and one of their most recent big investments – the surgical robot – Hugo. Together with the insulin pumps, Medtronic offers a sensor system that continuously monitors the level of glucose in a diabetes patient’s blood and automatically sends this data to the pump, which helps it dose insulin more correctly.

With a portfolio of over 49,000 patents and an impressive $2.5 billion annual spend on research and development, Medtronic is unmatched in their industry and continuously pursues new products and improves existing ones.

A dividend aristocrat with 25+ years of annual increases.

One thing with Medtronic is for certain - they take their dividends seriously. The company qualifies as a so-called Dividend Aristocrat, an entitlement earned by increasing your base dividend yearly for a minimum of 25 consecutive years.  

Medtronic's publicly listed competitors include multinational medical technology companies such as Abbott Laboratories, Boston Scientific, and Johnson & Johnson.